tbuckley/cabot-search huggingface dataset:
SP0150 The eu secretariat of the swedish disability movement
Authors: BJ Allardt Ljunggren
Journal: Annals of the Rheumatic Diseases (2001)

<h3></h3> Starting January 2001, Sweden has been chairing the European Union which has entailed a lot of work but also many possibilities to influence policies, proposals, activities etc. in the EU and also in the accession candidate countries. In order to make use of the chairmanship the Swedish Rheumatism Association and some of the other DPOs (Disabled People's Organisations) in Sweden have started a project. The project "The EU Secretariat 2001 of the Swedish Disability Movement" was started precisely in order to put focus on disability perspectives in the EU, by influencing public opinion, spreading information and increasing knowledge. The Secretariat will also arrange a European conference on the UN Standard Rules in April in Linkoeping in Sweden and offer accessibility advice to organisers of meetings and conferences during the Swedish presidency. The project has been funded by the Swedish Inheritance Fund. The secretariat has been situated in Stockholm in connexion to the offices of The Swedish Co-operative Body of Organisations of Disabled People, abbreviated HSO in Swedish. The project has been led by a steering group, where among other, the Swedish Rheumatism Association, the SRA, has been represented. Whereas the Swedish presidency in the EU focuses on the three Es Enlargement, Employment and Environment, the disability movement has chosen to interpret Environment more broadly and incorporate Accessibility into the concept. The secretariat has published some useful booklets, for instance one called "Disability perspective in the EU – a challenge to the Swedish Presidency".in which the Swedish disability movement presents suggestions on how the EU can work to strengthen the civil rights of disabled people in the member states. By using the suggestions as a base during the Presidency Sweden can contribute to an increasing EU- responsibility for the living conditions of disabled people in Europe. Please see www.hso.se/EU-secretariat.html/ for more information.
High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles
Authors: Jose C Villasboas, Patrizia Mondello, Angelo Fama, Melissa C. Larson, Andrew L. Feldman, Zhi-Zhang Yang, Ilia Galkin, Viktor Svekolkin, Ekaterina Postovalova, Alexander Bagaev, Pavel Ovcharov, Arina Varlamova, Sarah Huet, Bruno Tesson, Kaitlyn R McGrath, Susan L. Slager, Sergei Syrbu, Anne J. Novak, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Gilles Salles, James R. Cerhan, Stephen M. Ansell
Journal: Blood (2020)
CPX-351 Population Pharmacokinetics in Pediatric and Adult Patients with Acute Myeloid Leukemia (AML)
Authors: Qi Wang, Todd M. Cooper, Michael J. Absalon, E. Anders Kolb, Grygoriy Vasilinin, Nathalie H. Gosselin, Todd A. Alonzo, J.F. Marier
Journal: Blood (2020)
Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy
Authors: Alexis A. Thompson, Mark C. Walters, Markus Y Mapara, Janet L. Kwiatkowski, Lakshmanan Krishnamurti, Banu Aygun, Kimberly A. Kasow, Stacey Rifkin-Zenenberg, Manfred Schmidt, Jay DelCarpini, Francis J. Pierciey, Alexandra L. Miller, Meghan E. Gallagher, Ren Chen, Sunita Goyal, Julie Kanter, John F. Tisdale
Journal: Blood (2020)
"Detection of <i>BCR-ABL1</i>-like Subtype in Adult Acute Lymphoblastic Leukemia Using Digital Ncounter Nanostring Technology"
Authors: Dikshat Gopal Gupta, Neelam Varma, Shano Naseem, Man Updesh Singh Sachdeva, Pankaj Malhotra, Sreejesh Sreedharanunni, Subhash Varma, Parveen Bose, Minakshi Gupta, Palak Rana, Yogeshwar Binota, Preeti Sonam
Journal: Blood (2020)
Abstract 328: Enhanced Therapeutic Effects of Mesenchymal Stem Cells for Hindlimb Ischemia by a Nitric Oxide Hydrogel Through Mesenchymal-endothelial Transition
Authors: Kaiyue Zhang, Shang Chen, Haoyan Huang, Chen Wang, Zongjin Li
Journal: Circulation Research (2020)

Therapeutic angiogenesis with mesenchymal stem cells (MSCs) is promising for the clinical treatment of peripheral artery disease (PAD). However, the heterogeneous proangiogenic nature of MSCs is a key challenge in developing more effective treatments with MSCs for therapeutic angiogenesis purposes. Here, we propose to enhance the therapeutic function of human placenta-derived MSCs (hP-MSCs) in hindlimb ischemia therapy by using nitric oxide (NO)-releasing chitosan hydrogel (CS-NO). Our data showed that the co-transplantation of CS-NO hydrogel with hP-MSCs remarkably improved the grafting of hP-MSCs and ameliorated the functional recovery of ischemic hindlimbs. Moreover, we found that the neovascularization of damaged hindlimbs was significantly increased after co-transplanting CS-NO hydrogel and hP-MSCs, as confirmed by bioluminescence imaging (BLI). Further analysis revealed an endothelial-like status transformation of hP-MSCs in the presence of NO, which was identified as a potential mechanism contributing to the enhanced endothelium-protective and proangiogenic capacities of hP-MSCs that promote angiogenesis in mouse models of hindlimb ischemia. In conclusion, this study provides a promising approach for using NO hydrogel to improve the proangiogenic potency of MSCs in ischemic diseases, and the strategy used here facilitates the development of controlled-release scaffolds for enhancing the therapeutic efficiency of MSCs in angiogenic therapy.
A High Throughput Functional Screen Identifies a Novel Apex Inhibitor: Augments Cytotoxicity While Significantly Decreasing Genomic Evolution in Myeloma
Authors: Srikanth Talluri, Jialan Shi, Mychell Neptune-Buon, Subodh Kumar, Lakshmi B. Potluri, Nikhil C. Munshi, Masood A. Shammas
Journal: Blood (2020)
First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia Α
Authors: Amy D Shapiro, Barbara A. Konkle, Stacy E. Croteau, Wolfgang A. Miesbach, Charles Richard Morris Hay, Rashid Kazmi, Marina Mihova, Savita Rangarajan, John Pasi
Journal: Blood (2020)
Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone
Authors: Jesus F. San-Miguel, Herve Avet-Loiseau, Bruno Paiva, Shaji K. Kumar, Meletios A. Dimopoulos, Thierry Facon, Maria-Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michele Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J. Bahlis
Journal: Blood (2020)
AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial
Authors: Stephanie Sasse, Jesko Momotow, Annette Plütschow, Andreas Hüttmann, Nadezda Basara, Christian Koenecke, Sonja Martin, Martin Bentz, Christina Grosse-Thie, Sven Thorspecken, Maike de Wit, Carsten Kobe, Markus Dietlein, Bastian von Tresckow, Michael Fuchs, Peter Borchmann, Andreas Engert
Journal: Blood (2020)
Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome
Authors: N. Jewel Samadder, Douglas Riegert-Johnson, Lisa Boardman, Deborah Rhodes, Myra Wick, Scott Okuno, Katie L. Kunze, Michael Golafshar, Pedro L. S. Uson, Luke Mountjoy, Natalie Ertz-Archambault, Neej Patel, Eduardo A. Rodriguez, Blanca Lizaola-Mayo, Michael Lehrer, Cameron S. Thorpe, Nathan Y. Yu, Edward D. Esplin, Robert L. Nussbaum, Richard R. Sharp, Cindy Azevedo, Margaret Klint, Megan Hager, Sarah Macklin-Mantia, Alan H. Bryce, Tanios S. Bekaii-Saab, Aleksandar Sekulic, A. Keith Stewart
Journal: JAMA Oncology (2020)

<h3>Importance</h3> Hereditary factors play a key role in the risk of developing several cancers. Identification of a germline predisposition can have important implications for treatment decisions, risk-reducing interventions, cancer screening, and germline testing. <h3>Objective</h3> To examine the prevalence of pathogenic germline variants (PGVs) in patients with cancer using a universal testing approach compared with targeted testing based on clinical guidelines and the uptake of cascade family variant testing (FVT). <h3>Design, Setting, and Participants</h3> This prospective, multicenter cohort study assessed germline genetic alterations among patients with solid tumor cancer receiving care at Mayo Clinic cancer centers and a community practice between April 1, 2018, and March 31, 2020. Patients were not selected based on cancer type, disease stage, family history of cancer, ethnicity, or age. <h3>Exposures</h3> Germline sequencing using a greater than 80-gene next-generation sequencing platform. <h3>Main Outcomes and Measures</h3> Proportion of PGVs detected with a universal strategy compared with a guideline-directed approach and uptake of cascade FVT in families. <h3>Results</h3> A total of 2984 patients (mean [SD] age, 61.4 [12.2] years; 1582 [53.0%] male) were studied. Pathogenic germline variants were found in 397 patients (13.3%), including 282 moderate- and high-penetrance cancer susceptibility genes. Variants of uncertain significance were found in 1415 patients (47.4%). A total of 192 patients (6.4%) had incremental clinically actionable findings that would not have been detected by phenotype or family history–based testing criteria. Of those with a high-penetrance PGV, 42 patients (28.2%) had modifications in their treatment based on the finding. Only younger age of diagnosis was associated with presence of PGV. Only 70 patients (17.6%) with PGVs had family members undergoing no-cost cascade FVT. <h3>Conclusions and Relevance</h3> This prospective, multicenter cohort study found that universal multigene panel testing among patients with solid tumor cancer was associated with an increased detection of heritable variants over the predicted yield of targeted testing based on guidelines. Nearly 30% of patients with high-penetrance variants had modifications in their treatment. Uptake of cascade FVT was low despite being offered at no cost.
Safety and Efficacy of Four Drug Versus Three Drug Regimens Among Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
Authors: Saad Ullah Malik, Nazma Hanif, Priyanka Kumari, Khadija Noor Sami, Chase Warner, Yury Kachynski, Faiz Anwer
Journal: Blood (2020)
First It Was Masks; Now Some Refuse Testing for SARS-CoV-2
Authors: Rita Rubin
Journal: JAMA (2020)

John Heintzman, MD, MPH; Jean O'Malley, MPH; Miguel Marino, PhD; Jonathan V. Todd, PhD, MSPH; Kurt C. Stange, MD, PhD; Natalie Huguet, PhD; Rachel Gold, PhD, MPH
<i>Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma</i>
Authors: Gloria Iacoboni, Josu Iraola-Truchuelo, Nuria Martinez-Cibrian, Rebeca Bailén, Lucia Lopez Corral, Jose M. Sanchez, Manuel Guerreiro, ANA Carolina Carolina CABALLERO González, Alberto Mussetti, Juan-Manuel Sancho, Rafael Hernani, Carlos Solano, Anna Sureda Balari, Javier Briones, Alejandro Martin Garcia-Sancho, Mi Kwon, Juan Luis Reguera, Pere Barba
Journal: Blood (2020)
Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry*
Authors: G. Dobos, A. de Masson, C. Ram‐Wolff, M. Beylot‐Barry, A. Pham‐Ledard, N. Ortonne, S. Ingen‐Housz‐Oro, M. Battistella, M. d’Incan, J. Rouanet, F. Franck, M.D. Vignon‐Pennamen, N. Franck, A. Carlotti, S. Boulinguez, L. Lamant, T. Petrella, S. Dalac, P. Joly, P. Courville, J. Rivet, O. Dereure, F. Amatore, S. Taix, F. Grange, A. Durlach, G. Quéreux, N. Josselin, I. Moulonguet, L. Mortier, R. Dubois, E. Maubec, L. Laroche, L. Michel, I. Templier, S. Barete, C. Nardin, O. Augereau, B. Vergier, M. Bagot
Journal: British Journal of Dermatology (2020)

Background Primary cutaneous lymphomas (PCLs) are a heterogeneous group of T-cell (CTCL) and B-cell (CBCL) malignancies. Little is known about their epidemiology at initial presentation in Europe and about potential changes over time. Objectives The aim of this retrospective study was to analyse the frequency of PCLs in the French Cutaneous Lymphoma Registry (GFELC) and to describe the demography of patients. Methods Patients with a centrally validated diagnosis of primary PCL, diagnosed between 2005 and 2019, were included. Results The calculated incidence was unprecedently high at 1·06 per 100 000 person-years. The number of included patients increased yearly. Most PCL subtypes were more frequent in male patients, diagnosed at a median age of 60 years. The relative frequency of rare CTCL remained stable, the proportion of classical mycosis fungoides (MF) decreased, and the frequency of its variants (e.g. folliculotropic MF) increased. Similar patterns were observed for CBCL; for example, the proportion of marginal-zone CBCL increased over time. Conclusions Changes in PCL frequencies may be explained by the emergence of new diagnostic criteria and better description of the entities in the most recent PCL classification. Moreover, we propose that an algorithm should be developed to confirm the diagnosis of PCL by central validation of the cases.
Feasibility of Advanced Practice Nurse - Led Telehealth Service in Patients with Myeloproliferative Neoplasm in the Community: A Singapore Single-Centre Report
Authors: Chi Ching Lim, Xiaojuan Chen, Yee Mei Lee, Winnie ZY Teo, Moon Ley Tung, Wee-Joo Chng, Melissa Ooi
Journal: Blood (2020)
Evaluation of Trust Within a Community After Survivor Relocation Following the Great East Japan Earthquake and Tsunami
Authors: Krisztina Gero, Jun Aida, Katsunori Kondo, Ichiro Kawachi
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Trust is a core component of social cohesion, facilitating cooperation and collective action in the face of adversity and enabling survivors to remain resilient. Residential stability is an important prerequisite of developing trusting relations among community members. However, little is known about whether the movement of internally displaced persons (IDPs) after a disaster might change community relations. <h3>Objective</h3> We explored perceived changes in trust within 1 community directly impacted by the 2011 Great East Japan Earthquake and Tsunami. <h3>Design, Setting, and Participants</h3> This prospective cohort study examined survey data from 3594 residents of Iwanuma City, Japan, aged 65 years or older. Data were obtained from the Iwanuma Study—part of the Japan Gerontological Evaluation Study, a nationwide cohort study established in 2010—approximately 7 months before the disaster. All Iwanuma City residents age 65 years or older (8576 residents) were eligible to participate in 2010. The response rate was 59.0% (5058 residents). A follow-up survey was conducted in 2013, approximately 2.5 years after the disaster. Of the 4380 remaining participants who answered the baseline survey, 3594 were recontacted (follow-up rate, 82.1%). Data analysis was performed from July 1, 2019, to January 9, 2020. <h3>Exposures</h3> The number of temporarily relocated Iwanuma City survivors within 100 m and 250 m of a nonrelocated resident's home address. <h3>Main Outcomes and Measures</h3> Perceived changes in particularized trust (ie, trusting people from the same community) and generalized trust (trusting people from other communities) measured on a 5-point Likert scale. <h3>Results</h3> Among 3250 nonrelocated residents (1808 [55.6%] women; mean [SD] age, 76.5 [6.2] years) of Iwanuma City included in the analytic sample, multivariable-adjusted multinomial logistic regression analyses found that each standard deviation increase in the influx of internally displaced persons (1 SD = 11 IDPs) within 250 m of a resident's home address was associated with higher odds of a decrease in the resident's particularized and generalized trust (odds ratio, 1.17; 95% CI, 1.04-1.32). <h3>Conclusions and Relevance</h3> The influx of IDPs in the host community appeared to be associated with an erosion of trust among locals. To avoid the erosion of social cohesion after a disaster, it may be crucial to provide opportunities for social interaction between old and new residents of communities.
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Authors: Dienstl F, De Backer G, Cairns J, Pedersen F, Kala R, Boissel J-P, Schroeder R, Horgan J, Tognoni G
Journal: The Lancet (1988)
Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications
Authors: Qian Zhang, Yuan Rong, Kezhen Yi, Lanxiang Huang, Ming Chen, Fubing Wang
Journal: Theranostics (2020)

Circulating tumor cells (CTCs) are shed into the bloodstream from primary tumors and metastatic lesions and provide significant information about tumor progression and metastasis. CTCs contribute to tumor metastasis through the epithelial-to-mesenchymal transition (EMT). CTC clusters and stem-like phenotypes lead to a more aggressive and metastatic potential. CTCs retain the heterogeneity and imitate the nature of corresponding primary tumors. Therefore, it is important to use single-cell based analysis to obtain information on tumor heterogeneity and biology. CTCs are also good candidates for building preclinical models (especially 3D organoid cultures) for drug screening, disease modeling, genome editing, tumor immunity research, and organ-like biobank establishment. In this article, we summarize the current CTC capture technology, dissect the phenotypes associated with CTC metastasis, and review the progress in single-cell based analysis and preclinical modeling of the pattern and kinetics of CTCs. In particular, we discuss the use of CTCs to assess the progression of hepatocellular carcinoma (HCC).
RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma
Authors: Eugenio Morelli, Mariateresa Fulciniti, Mehmet K. Samur, Caroline Ribeiro, Leon Wert-Lamas, Annamaria Gulla, Anil Aktas-Samur, Katia Todoerti, Srikanth Talluri, Woojun Daniel Park, Jonathan E Henninger, Cinzia Federico, Giada Bianchi, Francesca Scionti, Yao Yao, Nicola Amodio, Charles Y Lin, Yu-Tzu Tai, Pierfrancesco Tassone, Antonino Neri, Dharminder Chauhan, Teru Hideshima, Richard A. Young, Kenneth Anderson, Carl D. Novina, Massimo Loda, Nikhil C. Munshi
Journal: Blood (2020)
Immunopathogenesis and treatment of cytokine storm in COVID-19
Authors: Jae Seok Kim, Jun Young Lee, Jae Won Yang, Keum Hwa Lee, Maria Effenberger, Wladimir Szpirt, Andreas Kronbichler, Jae Il Shin
Journal: Theranostics (2020)

Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine storm refers to a set of clinical conditions caused by excessive immune reactions and has been recognized as a leading cause of severe COVID-19. While comparisons have been made between COVID-19 cytokine storm and other kinds of cytokine storm such as hemophagocytic lymphohistiocytosis and cytokine release syndrome, the pathogenesis of cytokine storm has not been clearly elucidated yet. Recent studies have shown that impaired response of type-1 IFNs in early stage of COVID-19 infection played a major role in the development of cytokine storm, and various cytokines such as IL-6 and IL-1 were involved in severe COVID-19. Furthermore, many clinical evidences have indicated the importance of anti-inflammatory therapy in severe COVID-19. Several approaches are currently being used to treat the observed cytokine storm associated with COVID-19, and expectations are especially high for new cytokine-targeted therapies, such as tocilizumab, anakinra, and baricitinib. Although a number of studies have been conducted on anti-inflammatory treatments for severe COVID-19, no specific recommendations have been made on which drugs should be used for which patients and when. In this review, we provide an overview of cytokine storm in COVID-19 and treatments currently being used to address it. In addition, we discuss the potential therapeutic role of extracorporeal cytokine removal to treat the cytokine storm associated with COVID-19.
FRI0211 VASCULITIS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: FRENCH MULTICENTER CASE CONTROL STUDY
Authors: A. Roupie, B. Terrier, P. Fenaux, O. Fain, A. Mekinian
Journal: Annals of the Rheumatic Diseases (2020)

Background: Myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasms (MDS/MPN) can be associated with vasculitis. Objectives: In this nationwide study by the “French Network of dysimmune disorders associated with hemopathies” (MINHEMON) the objective was to evaluate characteristics, treatment and outcome of vasculitis MDS-MDS/MPN. Methods: Retrospective analysis of patients that presented a MDS/MPN associated with vasculitis and compared the overall survival and acute leukemia with MDS without vasculitis. Results: Seventy patients with vasculitis and MDS/MPN were included, with a median age of 71.5 [21-90] years and male/female ratio of 2.3. Vasculitis was diagnosed prior to MDS/MPN in 31 patients (44.3%), with a median time of 27 months [1-120] between two diagnosis, and after in 20 patients (6 months [1-59]). In comparison to 183 MDS/MPN without dysimmune features showed no difference in MDS/MPN subtypes distribution nor median IPSS/CPSS scores in patients with and without vasculitis. The vasculitis subtypes was giant-cell arteritis (GCA) in 24 patients (34%). Eleven patients (20%) had Behçet’s-like syndrome and 6 patients (9%) presented with polyarteritis nodosa. Steroids (60 mg/day [0-500] of prednisone equivalent) were used as first-line therapy for MDS/MPN vasculitis in 64/70 patients (91%) and 41 (59%) received combined immunosuppressive therapies during the follow-up. After the follow-up of 33.2 months [1-162], 31 patients (44%) finally experienced sustained remission. At least one relapse during the 33.2 months [1-162] follow-up occurred in 43 patients (61%). Relapse rates were higher in patients treated by DMARDs (odds ratio at 4.86 [95% CI 1.38 - 17.10]), but did not differ from biologics (odds ratio 0.59 [95% CI 0.11-3.20]) and azacytidine (odds ratio 1.44 [95% CI 0.21-9.76]) (steroids considered as reference). Overall survival and progression to acute myeloid leukemia in MDS/MPN vasculitis were not significantly different from MDS/MPN patients without any dysimmune features (p=0.5). Conclusion: This first largest study of MDS/MPN vasculitis show no correlation of vasculitis subtypes with various subtypes and severity of MDS/MPN, and no significant impact of vasculitis on overall survival and progression to acute myeloid leukemia. The high relapse rats and steroid dependence raise the question of combined therapies to steroids. Whereas DMARDs use seem to be avoid specific azacytidine therapy could be considered for even low-risk MDS/MPN vasculitis. Acknowledgments: minhemon gfm gfev Disclosure of Interests: None declared
Tet2 Inactivation Enhances the Anti-Tumor Activity of Tumor-Infiltrating Lymphocytes (TILs) to Curtail Melanoma Growth
Authors: Minjung Lee, Jianfang Li, Shaohai Fang, Joanna Zhang, Anh Tran Tram Vo, Wei Han, Hongxiang Zeng, Sevinj Isgandarova, Margarita Martinez Moczygemba, Yubin Zhou, Jia Li, Deqiang Sun, Yun Huang
Journal: Blood (2020)
Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups
Authors: Josep-Maria Ribera, Mireia Morgades, Rosa Coll, Jose Luis Lopez Lorenzo, Pau Montesinos, Rosario Varela, Mónica Cabrero, Ignacio Gómez-Centurión, M. Dolores Morales, Antoni Garcia-Guiñon, Guiomar Bautista, Pilar Herrera Puente, Laura Llorente, Irene García-Cadenas, Pere Barba, Maria Calbacho, Cristina Gil, Maria Angeles Foncillas, María Teresa Artola, Rafael De La Camara, Jose Luis Piñana Sanchez
Journal: Blood (2020)